StoneWise (望石智慧)

Beijing AI small-molecule company: a 3D molecular-generation platform sold to pharma, plus an in-house HPK1 inhibitor in Phase I.

1. Core Product / Service

StoneWise was founded in 2018 and is based in Beijing [1]. Its core is a 3D small-molecule generation model. Around it the company has built:

• a multi-agent system for early-stage R&D;
• a "digital compass" data system;
• an integrated dry/wet R&D platform [4].

It sells AI-driven molecular design, custom model training and compound screening to pharma companies and research institutes. It also runs its own pipeline [3].

Pipeline.

• SWA1211. An oral HPK1 inhibitor designed with the company's generative model. The company says it received clinical clearance in both China and the US in June 2025 [3]. China's trial registry (CTR20251571, first posted 19 May 2025) lists a first-in-human, open-label, dose-escalation Phase I in advanced solid tumors, planning 60 patients [5][6].
• The company says it is advancing more than ten internal projects, some of them clinical [3]. Only SWA1211 is identified publicly.

Wet-lab model. StoneWise says it runs its own standardized chemistry lab, which synthesizes AI-generated molecules, tests their activity and drug-likeness, and feeds the results back into its models [3]. It also cites a physical compound library and a joint lab with Peking University, set up in 2022 and later designated a Beijing key laboratory for intelligent drug R&D [3]. Lab size, headcount and CRO use are not disclosed. These are company statements.

2. Target Users & Pain Points

• Pharma and biotech medicinal-chemistry teams that want faster hit finding and lead optimization. The company claims hit cycles of 1–6 months and 70–80% lower R&D cost [3] (self-reported). It cites more than 100 partners, including several top-20 global pharma companies, Qilu and Chipscreen [3].
• Domestic-compute buyers. In May 2026 StoneWise signed a three-way agreement with Guangzhou Pharmaceutical Holdings and Huawei. Huawei supplies a private deployment on domestic compute, and the pharma partner supplies real R&D use cases [4].

3. Competitive Landscape

4. Unique Observations

• It has moved toward platform, not away from it. By 2026 StoneWise calls itself a "pharma AI infrastructure provider" offering foundation models and full-chain agents [4]. Many peers instead pivot from services to pipeline. SWA1211 serves as a showcase that the platform can reach the clinic.
• Funding has been quiet since 2021. The only public large round is the US$100M Series B/B+ in April 2021 [1]. Searches found no later disclosed financing, which may explain the platform-revenue emphasis.
• SWA1211 sits in a crowded HPK1 field. BeiGene, Treadwell and Glenmark all have HPK1 programs in early clinical trials [5].

5. Financials / Funding

• Total raised (disclosed): about US$110M or more.
• Revenue and valuation: not disclosed.

6. People & Relationships

• Founder & CEO: 周杰龙 (Zhou Jielong). He holds AI bachelor's and master's degrees from Beijing Institute of Technology, has over 20 years in AI algorithms, and was formerly a chief architect at Baidu [1][3].
• Academic partner: Peking University, through a joint lab; a 2023 Nature Machine Intelligence paper came out of it [3].
• Investors: Legend Capital, Lightspeed China Partners, Longhill Capital, Linear Capital.
• Peers: mindrank, metis-techbio, helixon-therapeutics, revir-therapeutics.

Sources

1. Yicai Global (Series B/B+) — https://www2.yicaiglobal.com/news/lightspeed-greater-bay-area-fund-pour-usd100-million-into-drug-ai-startup-stonewise
2. TechNode (Series A) — https://technode.com/2020/03/16/ai-drug-development-platform-raises-10-million-in-series-a/
3. Pharnexcloud (company interview) — https://www.pharnexcloud.com/zixun/shiye/zjgd_293471
4. 36Kr (2026 positioning) — https://www.36kr.com/p/3866854221698313
5. AllSci (SWA1211 Phase I) — https://allsci.com/news/chinas-stonewise-puts-novel-hpk1-inhibitor-to-first-in-human-test/
6. Pharnexcloud trial record CTR20251571 — https://www.pharnexcloud.com/data/lcsy_070f7147a77170ce87027c15995602e1.html